Medical Therapeutics

Ogma Scientific

Brief Description

Ogma Scientific works with clients in the energy, mining and agriculture sectors and clients in the chemical industry to identify innovative treatment strategies for problems in industrial ecosystems. Our high-throughput screening services are uniquely tailored to identify successful treatments to stop undesirable microbial activity that impacts industrial processes. Examples include biosouring in the oil sector and acid mine drainage in the mining sector. Biosouring alone, caused by the inadvertent stimulation of microbial activity during oil or gas recovery, costs the...

Nurix

Brief Description

Nurix is pioneering rational drug design in the emerging field of protein regulation by targeting E2 conjugating enzymes and E3 ligases that control the Ubiquitin Proteasome System (UPS).

Regulation of protein stability by the UPS is modulated by the activity of these E2 and E3 enzymes, which control the tagging of proteins with ubiquitin for degradation by the proteasome. The human genome encodes approximately 1,000 different E3 ligases and 60 E2 enzymes. A number of these ligases recently have been shown to play key roles in human diseases, particularly in cancer...

suitX

Brief Description

suitX brought advanced accessible exoskeletons to industrial and medical markets with funding from venture capital, industry, and government.

Formerly known as U.S. Bionics.

Acquired by Ottobock in 2021.

Timeline 2011. Company founded. 2021. Acquired by Ottobock. Inventors

Homayoon Kazerooni, Adam Zoss, Andre Nguyen Van Qui, Bradley Perry, Christina Yee, Daniel Merala, David Cuban, Dong-Jin Hyun, Dylan Fairbanks, Erich Hacker, Han Woong Bae, James Alden Hatch, Jason Reid, JiaLong James Ren, Jing Song Huang, JJ Kuwata...

Stylus Medicine

Brief Description

Stylus Medicine is on a mission to develop next-generation therapies for disease, based on the pioneering work of leaders in the fields of genome engineering and chromatin regulation.

Timeline 2022. Company founded. Inventor

Patrick David Hsu

Spotlight Therapeutics

Brief Description

Developer of next-generation gene editing therapeutics in a preclinical pipeline. The company creates programmable nucleases that selectively target and edit specific cell populations directly in the body. These engineered nucleases will enable direct intervention in vivo like a true administered biologic. Spotlight Therapeutics co-founders include Dr. Patrick Hsu, a UC Berkeley Assistant Professor of Bioengineering and co-founder of the Arc Institute.

Timeline 2017. Company founded. Inventors

Colleen McGourty, Lorena de Onate, Ross...

Caribou Biosciences Inc.

Brief Description

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T cell platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases.

...

Scribe Therapeutics

Brief Description

Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders. The molecular engineering company was spun out of discoveries in the lab of UC Berkeley Professor of Biochemistry, Biophysics and Structural Biology and Nobel Laureate Jennifer Doudna. Doudna co-founded Scribe with company CEO Benjamin Oakes, who received a PhD in Molecular and Cellular Biology from UC Berkeley in 2017, where he worked in the Doudna Lab and Savage Lab, UC Berkeley Associate Professor of...

Iaterion

Brief Description

Iaterion is a biopharma company developing novel therapeutics for women's health and diseases. The company develops targeted selective nuclear receptor drugs addressing multiple indications encountered by women and focuses on novel drugs as an alternative to menopausal hormone therapy (MHT). The company was founded to commercialize a novel discovery made by UC Berkeley Adjunct Professor in the Department of Nutritional Sciences Dale Leitman, MD, PhD, for nuclear receptors reprogramming (NRRP) agents.

Iaterion's team brings decades of experience in the bio-...

GenEdit, Inc.

Brief Description

GenEdit develops innovative therapies through targeted delivery of genetic medicines. The GenEdit founders share the vision that recent scientific advancements in engineering CRISPR components and delivery vehicles offer a groundbreaking opportunity to develop safe and effective medicines for genetic diseases.

The company's proprietary Polymer nanoparticle can deliver CRISPR protein and gRNA. CRISPR in a protein form has many advantages, delivery has been a challenge limiting its application. To deliver CRISPR protein, encapsulation of CRISPR ribonucleoprotein (RNP...

Redwood Bioscience Inc.

Brief Description

Redwood Bioscience, Inc. develops a protein-chemical engineering technology to produce antibody-drug conjugates and other semi-synthetic biotherapeutics. The company offers SMARTag site-specific protein modification and cytotoxin-linker technologies that enable the generation of homogenous bioconjugates engineered to enhance potency, safety, and stability. Its SMARTag platform provides precise payload positioning and defined stoichiometry of payload-protein ratios. The company was incorporated in 2008 and is based in Emeryville, California. Redwood Bioscience, Inc....